A Breakthrough 6-Month Regimen for Drug-Resistant TB

Clinicians worldwide have long sought shorter and less toxic options for managing drug-resistant tuberculosis. Consequently, a new phase 3 pragmatic trial has evaluated an oral, six-month rifampicin-resistant TB treatment strategy. This study demonstrated that the shorter course matches the efficacy of traditional nine-month protocols. As a result, this breakthrough could simplify care and improve patient compliance in high-burden settings like India.

Designing the Rifampicin-Resistant TB Treatment Trial

The randomized, open-label, noninferiority BEAT Tuberculosis trial took place across several clinical sites in South Africa. Researchers enrolled participants who were six years of age or older with pulmonary rifampicin-resistant tuberculosis. Notably, the trial included pregnant or breastfeeding women and patients with fluoroquinolone-resistant disease. Investigators randomly assigned 203 patients to the experimental six-month strategy and 200 patients to the control group. The experimental regimen utilized bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine. Meanwhile, the control group received the standard South African nine-month treatment regimen. Crucially, clinicians adjusted regimens in both cohorts based on second-line drug susceptibility testing.

Efficacy and Safety Findings

First, the primary efficacy end point focused on a successful treatment outcome at 76 weeks. In the trial-strategy group, 86.1% of participants achieved a successful outcome, compared to 86.0% in the control group. Therefore, the shorter strategy proved noninferior to the standard of care. Additionally, the risk of serious side effects did not differ significantly between the two groups. Specifically, adverse events of grade 3 or higher occurred in 31.2% of the trial-strategy cohort and 37.0% of the control cohort. Ten patients in each group died during the study. Overall, these findings indicate that the shorter strategy is both safe and effective.

Clinical Implications for Global Health

Because drug-resistant tuberculosis is a global health threat, shorter treatment regimens are highly valuable. Patients are far more likely to complete a six-month course than a nine-month regimen. Consequently, this strategy can significantly reduce treatment default rates in high-burden regions. Furthermore, the inclusion of children and pregnant women makes these findings highly generalizable. Clinicians can confidently apply this protocol to diverse patient populations. Ultimately, this approach will help healthcare systems optimize resource allocation while delivering high-quality care.

Frequently Asked Questions

Q1: What was the primary finding of the BEAT Tuberculosis trial?

Specifically, the trial found that a six-month treatment strategy was noninferior to the standard nine-month regimen. Both strategies achieved similar safety profiles.

Q2: Which drugs did the investigators use in the experimental six-month regimen?

The experimental regimen utilized bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine. Additionally, clinicians adjusted these medications based on drug susceptibility testing.

Q3: Did the study include pregnant women and children?

Yes, because investigators aimed for a pragmatic population, they included children and pregnant women.

References

1. Conradie F et al. A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. N Engl J Med. 2026 Jun 25. doi: 10.1056/NEJMoa2503687. PMID: 42341301.
2. World Health Organization. WHO issues rapid communication on key updates to the treatment of drug-resistant tuberculosis. Geneva: WHO. 2024.
3. endTB Consortium. Major advance in the fight against MDR-TB: four new short and effective treatments from independent clinical trials approved by the WHO. 2024.